203 related articles for article (PubMed ID: 28088784)
1. A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma.
Jung SH; Lee HJ; Lee YK; Yang DH; Kim HJ; Rhee JH; Emmrich F; Lee JJ
Oncotarget; 2017 Jun; 8(25):41538-41548. PubMed ID: 28088784
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of intracellular immune checkpoint-silenced DC vaccine.
Wang D; Huang XF; Hong B; Song XT; Hu L; Jiang M; Zhang B; Ning H; Li Y; Xu C; Lou X; Li B; Yu Z; Hu J; Chen J; Yang F; Gao H; Ding G; Liao L; Rollins L; Jones L; Chen SY; Chen H
JCI Insight; 2018 Feb; 3(3):. PubMed ID: 29415891
[TBL] [Abstract][Full Text] [Related]
3. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
4. DC in multiple myeloma immunotherapy.
Turtle CJ; Brown RD; Joshua DE; Hart DN
Cytotherapy; 2004; 6(2):128-37. PubMed ID: 15203989
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.
Hobo W; Strobbe L; Maas F; Fredrix H; Greupink-Draaisma A; Esendam B; de Witte T; Preijers F; Levenga H; van Rees B; Raymakers R; Schaap N; Dolstra H
Cancer Immunol Immunother; 2013 Aug; 62(8):1381-92. PubMed ID: 23728352
[TBL] [Abstract][Full Text] [Related]
7. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
[TBL] [Abstract][Full Text] [Related]
8. Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells.
Vo MC; Nguyen-Pham TN; Lee HJ; Jung SH; Choi NR; Hoang MD; Kim HJ; Lee JJ
Oncotarget; 2017 Jul; 8(28):46047-46056. PubMed ID: 28512265
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial.
Cox MC; Castiello L; Mattei M; Santodonato L; D'Agostino G; Muraro E; Martorelli D; Lapenta C; Di Napoli A; Di Landro F; Cangemi M; Pavan A; Castaldo P; Hohaus S; Donati S; Montefiore E; Berdini C; Carlei D; Monque DM; Ruco L; Prosperi D; Tafuri A; Spadaro F; Sestili P; Spada M; Dolcetti R; Santini SM; Rozera C; Aricò E; Capone I; Belardelli F
Clin Cancer Res; 2019 Sep; 25(17):5231-5241. PubMed ID: 31171545
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma.
Cohen S; Haimovich J; Hollander N
J Immunol; 2009 Feb; 182(3):1667-73. PubMed ID: 19155516
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma.
Hájek R; Butch AW
Med Oncol; 2000 Feb; 17(1):2-15. PubMed ID: 10713654
[TBL] [Abstract][Full Text] [Related]
13. Optimizing dendritic cell-based immunotherapy in multiple myeloma.
Yi Q; Desikan R; Barlogie B; Munshi N
Br J Haematol; 2002 May; 117(2):297-305. PubMed ID: 11972511
[TBL] [Abstract][Full Text] [Related]
14. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
Röllig C; Schmidt C; Bornhäuser M; Ehninger G; Schmitz M; Auffermann-Gretzinger S
J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.
Hildenbrand B; Sauer B; Kalis O; Stoll C; Freudenberg MA; Niedermann G; Giesler JM; Jüttner E; Peters JH; Häring B; Leo R; Unger C; Azemar M
Prostate; 2007 Apr; 67(5):500-8. PubMed ID: 17262804
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
Katano M; Morisaki T; Koga K; Nakamura M; Onishi H; Matsumoto K; Tasaki A; Nakashima H; Akiyoshi T; Nakamura M
Anticancer Res; 2005; 25(6A):3771-6. PubMed ID: 16302738
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.
Zahradova L; Mollova K; Ocadlikova D; Kovarova L; Adam Z; Krejci M; Pour L; Krivanova A; Sandecka V; Hajek R
Neoplasma; 2012; 59(4):440-9. PubMed ID: 22489700
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.
Rosenblatt J; Avivi I; Vasir B; Uhl L; Munshi NC; Katz T; Dey BR; Somaiya P; Mills H; Campigotto F; Weller E; Joyce R; Levine JD; Tzachanis D; Richardson P; Laubach J; Raje N; Boussiotis V; Yuan YE; Bisharat L; Held V; Rowe J; Anderson K; Kufe D; Avigan D
Clin Cancer Res; 2013 Jul; 19(13):3640-8. PubMed ID: 23685836
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory effect of DC/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy.
Zhao X; Ji CY; Liu GQ; Ma DX; Ding HF; Xu M; Xing J
Int J Clin Exp Pathol; 2015; 8(10):13146-55. PubMed ID: 26722513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
